VaxRabeo (rabies vaccine (inactivated) for human)

Where it stands

VaxRabeo (rabies vaccine, inactivated, for human use) from Sanofi Winthrop Industrie received a CHMP positive opinion on 2026-09-17. The records show the status as 'Opinion' and no approval date, so the European Commission (EC) has not yet issued a marketing authorisation according to the data provided.

The proposed indication is pre-exposure and post-exposure prophylaxis against rabies in all age groups. The records do not give the wording of the product information, dosing schedules, or the data supporting the opinion, so this analysis cannot comment on the clinical package.

The records include an estimated EC decision date of 2026-11-23. This is not an official date. It is calculated as the CHMP opinion date plus 67 days, the standard Commission decision period. The actual date could be earlier or later.

Regulatory pathway and designations

A CHMP opinion is the scientific recommendation of the European Medicines Agency's committee for human medicines. It is not itself a marketing authorisation. In the centralised procedure, the EC normally adopts a legally binding decision after the opinion, following its internal consultation steps with Member States. A positive opinion usually leads to authorisation, but the records do not give a basis for assessing timing risks beyond the standard period.

The records list no designations for VaxRabeo, so no orphan, PRIME, or other special status is recorded. The records also do not say whether this is a new active substance, a line extension, or a new brand of an existing vaccine, nor whether the procedure involved accelerated assessment. These points are not covered in the data provided.

The therapeutic area is rabies, and the product is a vaccine, which is relevant to how it would be positioned in both pre-exposure and post-exposure settings. Beyond the indication wording, the records give no information on how it differs from other rabies vaccines.

Safety and pharmacovigilance

The records contain no safety data, adverse event information, risk management plan details, or post-authorisation commitments for VaxRabeo. No safety conclusions can be drawn from the data provided.

As general procedure, a newly authorised vaccine in the EU would be covered by pharmacovigilance obligations, including a risk management plan and routine safety reporting. Whether additional monitoring or specific conditions apply to VaxRabeo is not stated in the records and should be confirmed in the EC decision and the EPAR once published.

What to watch

The key event is the EC decision, estimated for around 2026-11-23 on the standard 67-day basis. This is an estimate, not an official date. Confirmation will come from publication of the Commission decision and the associated product information.

Once authorised, the EPAR and the final product information should clarify the points the records do not cover, including the clinical evidence, the dosing regimens for pre- and post-exposure use, any age-specific considerations, and any conditions or additional monitoring requirements.

Market launch timing, national reimbursement, and tender or procurement dynamics are not covered in the records and cannot be assessed here.